Question: Which genes have been proposed as potential candidates for gene therapy of heart failure?

Context:
The molecular abnormalities underlying HF are discussed along with potential targets for gene therapy, focusing on SERCA2a.
The aim of this study was to improve cardiac function in chronic HF by overexpressing constitutively active inhibitor-1 (I-1c) 
In summary, I-1c overexpression using BNP116 improves cardiac function in a clinically relevant model of ischemic HF.
therapeutic activation of YAP or its downstream targets, potentially through AAV-mediated gene therapy, may be a strategy to improve outcome after MI
calcium up-regulation by AAV1/SERCA2a gene therapy is safe and of potential benefit in advanced heart failure patients. 
Survivin gene therapy can attenuate the progression of LV systolic dysfunction in doxorubicin cardiomyopathy.
Heart failure-inducible molecular targeting of PP1β has potential as a novel therapeutic strategy for heart failure.
The recent successful and safe completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium ATPase pump (SERCA2a), along with the start of more recent phase 1 trials, opens a new era for gene therapy for the treatment of heart failure.
Our results present a strong rationale for a clinical trial of S100A1 gene therapy for human heart failure that could potentially complement current strategies to treat end-stage heart failure.
S100A1, a positive inotropic regulator of myocardial contractility, becomes depleted in failing cardiomyocytes in humans and animals, and myocardial-targeted S100A1 gene transfer rescues cardiac contractile function by restoring sarcoplasmic reticulum calcium (Ca(2+)) handling in acutely and chronically failing hearts in small animal models.
Use of gene therapy for heart failure is gaining momentum as a result of the recent successful completion of phase II of the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial, which showed clinical safety and efficacy of an adeno-associated viral vector expressing sarco-endoplasmic reticulum calcium ATPase (SERCA2a).
The recent successful and safe completion of a phase 2 trial targeting the cardiac sarcoplasmic/endoplasmic reticulum Ca2+ ATPase pump (SERCA2a) has the potential to open a new era for gene therapy for heart failure.
The recent successful and safe completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium ATPase pump (SERCA2a) has the potential to open a new era for gene therapy in the treatment of heart failure.
AIMS: Impaired myocardial sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) activity is a hallmark of failing hearts, and SERCA2a gene therapy improves cardiac function in animals and patients with heart failure (HF).

Answer: There are at least 6 genes which have been proposed as potential candidates of gene therapy in heart failure.
1. Cardiac Sarco-Endoplasmic Reticulum Calcium ATPase 2A (SERCA2A)
2. Inhibitor 1 (I-1) of Protein Phosphatase 1B
3. Protein Phosphatase 1B (PP1B)
4. Yes Associated Protein (YAP)
5. Survivin
6. S100A1
Exact answer: Sarco-Endoplasmic Reticulum Calcium ATPase 2A
(SERCA2A)
Inhibitor 1 of Protein Phosphatase 1B
(I-1)
Protein Phosphatase 1B
(PP1B)
Yes Associated Protein
(YAP)
Survivin
S100A1